文献速递其他结缔组织病

复方磺胺甲噁唑改善抗黑色素瘤分化相关基因5抗体阳性皮肌炎患者预后

Compounded sulfamethoxazole improved the prognosis of dermatomyositis patients positive with anti-melanoma differentiation-associated gene 5.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

本研究回顾性纳入2018年6月至2021年10月本中心连续新发抗MDA5抗体阳性皮肌炎患者,按是否初始预防性使用复方磺胺甲噁唑分为两组,比较12个月内死亡率和严重感染发生率。结果显示coSMZ组死亡率、PJP发生率和致死性感染发生率均低于非coSMZ组,调整混杂因素后预防性使用coSMZ与PJP发生率呈负相关。

要点

  • coSMZ组12个月内死亡率18.8%,低于非coSMZ组的51.1%(P<0.001)。
  • coSMZ组PJP发生率6.8%,低于非coSMZ组的15.2%(P=0.040)。
  • 调整后预防性使用coSMZ与PJP发生率负相关,调整OR 0.299(95%CI 0.102-0.878),P=0.028。

核心结论

  • 预防性使用复方磺胺甲噁唑是改善抗MDA5抗体阳性皮肌炎患者预后的有效且安全的方式,通过预防PJP发生实现。

研究设计与样本

  • 回顾性纳入2018年6月至2021年10月本中心连续新发抗MDA5抗体阳性皮肌炎患者,随访超过12个月,按初始是否预防性使用coSMZ分为coSMZ组(n=121)和非coSMZ组(n=93)。

主要发现

  • coSMZ组12个月内死亡率为18.8%,非coSMZ组为51.1%(P<0.001)。
  • coSMZ组PJP发生率为6.8%,非coSMZ组为15.2%(P=0.040)。
  • coSMZ组致死性感染发生率为16.1%,非coSMZ组为3.3%(P=0.001)。
  • 调整年龄、性别、病程、外周血淋巴细胞计数、抗MDA5抗体滴度、磨玻璃影评分和治疗后,预防性使用coSMZ与PJP发生率呈负相关,调整OR为0.299(95%CI 0.102-0.878),P=0.028。

关键数值与推荐

  • coSMZ每片含磺胺甲噁唑400 mg和甲氧苄啶80 mg。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Mortality of dermatomyositis patients positive with anti-melanoma differentiation-related gene 5 antibody (anti-MDA5-DM) is alarming, especially during the first several months. Infection is an important cause of early death. As there are no reports regarding the effect of prophylactic use of compounded sulfamethoxazole (coSMZ; each tablet contains 400 mg of sulfamethoxazole and 80 mg of trimethoprim) in anti-MDA5-DM patients, we conducted this study to evaluate the efficacy of coSMZ in reducing the incidence of Pneumocystis jirovecii pneumonia (PJP). METHODS: Consecutive patients with new-onset anti-MDA5-DM from June 2018 to October 2021 in our centre were retrospectively reviewed for >12 months. They were divided into two groups-coSMZ and non-coSMZ-based on the initial use of prophylactic coSMZ. Mortality and the incidence of severe infection within 12 months were compared between two groups. RESULTS: Compared with the non-coSMZ group (n = 93), the coSMZ group (n = 121) had lower mortality (18.8% vs 51.1%; P < 0.001) and a lower incidence of PJP (6.8% vs 15.2%; P = 0.040) and fatal infection (16.1% vs 3.3%; P = 0.001) during the first 12 months from diagnosis. After adjusting for age, gender, disease duration, peripheral blood lymphocyte count, anti-MDA5 antibody titres, ground-glass opacity scores and treatments, an inverse association was revealed between the prophylactic use of coSMZ and incidence of PJP [adjusted odds ratio 0.299 (95% CI 0.102-0.878), P = 0.028]. CONCLUSION: Prophylactic use of coSMZ is an effective and safe way to improve the prognosis of anti-MDA5-DM patients by preventing the incidence of PJP.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Liu L, Zhang Y, Liu S, et al. Compounded sulfamethoxazole improved the prognosis of dermatomyositis patients positive with anti-melanoma differentiation-associated gene 5. Rheumatology (Oxford). 2023. PMID: 36702462. doi:10.1093/rheumatology/kead034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。